학술저널
Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta protofibrils and was approved by the FDA on July 6, 2023. This case report describes the clinical setting for lecanemab administration, as well as the clinical course and adverse events following six months of treatment in four patients with Alzheimer’s disease dementia. These findings may serve as foundational information for future clinical practice and research involving monoclonal antibody therapies for Alzheimer’s disease.
서 론
증 례
고 찰
REFERENCES
(0)
(0)